Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Estimation of low-density lipoprotein cholesterol (LDL-C) using the Friedewald (FR) formula is often inaccurate when triglycerides are elevated or VLDL particle composition is altered. We hypothesized that LDL-C estimation by the FR formula and other measurement methods might also be inaccurate in individuals treated with a cholesteryl ester transfer protein (CETP) inhibitor. An assay comparison study was conducted using pre and posttreatment serum samples from 280 of the 811 patients treated with the CETP inhibitor anacetrapib in the DEFINE study (determining the efficacy and tolerability of CETP inhibition with anacetrapib). After 24 weeks of treatment with anacetrapib, mean LDL-C values by FR formula, Roche direct method (RDM) and Genzyme direct method (GDM) deviated from that measured by the β-quantification (BQ) reference method by -12.2 ± 7.5, -10.2 ± 6.6, -10.8 ± 8.8 mg/dl, respectively. After treatment with anacetrapib, the FR formula and detergent-based direct methods provided lower LDL-C values than those obtained by the BQ reference method. The bias by the FR formula appeared to be due to an overestimation of VLDL-C by the TG/5 component of the formula. Evaluation of the clinical significance of these findings awaits comprehensive lipid and cardiovascular outcome data from ongoing Phase III clinical studies of anacetrapib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inhibitors of CETP can markedly increase high-density lipoprotein cholesterol, and two members of this class in advanced development, anacetrapib and evacetrapib, equally lower LDL-C by 25–40%.75,76”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196701052760107 · Cited by 1,910
HATCH, F. T., & LEES, R. S. (1968) · Advances in Lipid Research · doi:10.1016/b978-1-4831-9942-9.50008-5 · Cited by 1,234
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Self-citationBachorik, P. S., & Ross, J. W. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.10.1414 · Cited by 412
Miller, W. G., Myers, G. L., Sakurabayashi, I., Bachmann, L. M., Caudill, S. P., Dziekonski, A., Edwards, S., Kimberly, M. M., Korzun, W. J., Leary, E. T., et al. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.142810 · Cited by 386
Self-citation
Cited by
Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
“of CETP can markedly increase high-density lipoprotein cholesterol, and two members of this class in advanced development, anacetrapib and evacetrapib, equally lower LDL-C by 25–40%.(75,76) The mechan-”
Effects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Trials and Tribulations of CETP Inhibitors
Tall, A. R., & Rader, D. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311978 · Cited by 305
“This supposition is supported by studies performed in a subset of patients in the DEFINE (Determining the Efficacy and tolerability of CETP inhibition with anacetrapib) trial which showed a larger absolute reduction in LDL-C by anacetrapib in patients with higher LDL-C at baseline compared with those with lower levels…”
ResultLDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274
Nicholls, S. J., Ditmarsch, M., Kastelein, J. J., Rigby, S. P., Kling, D., Curcio, D. L., Alp, N. J., & Davidson, M. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01936-7 · Cited by 174
Self-citationCholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
Armitage, J., Holmes, M. V., & Preiss, D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.072 · Cited by 140
“calculation by the Friedewald equation provided estimates of LDL-C reduction that were approximately double the reduction by beta quantification (36,39).”
MethodNew therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht088 · Cited by 99
“20%) reduced LDL-C levels by 40% and increased HDL-C levels by 138% with no changes in blood pressure or serum aldosterone levels.(41,42) This study set the stage for the REVEAL phase III study which will examine major coronary events in 30 000 patients with coronary heart disease, cerebrovascular atherosclerotic dise…”
BackgroundNurmohamed, N. S., Ditmarsch, M., & Kastelein, J. J. P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab350 · Cited by 107
Gotto, A. M., Cannon, C. P., Li, X. S., Vaidya, S., Kher, U., Brinton, E. A., Davidson, M., Moon, J. E., Shah, S., Dansky, H. M., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.041 · Cited by 86
“A subsequent assay comparison study indicated that the Friedewald equation, the method used to calculate LDL cholesterol in DEFINE, underestimates LDL cholesterol levels after treatment with anacetrapib, compared with the reference b-quantification method.(5) Treatment with anacetrapib for 76 weeks was well tolerated,…”
MethodSelf-citationBallantyne, C. M., Ditmarsch, M., Kastelein, J. J., Nelson, A. J., Kling, D., Hsieh, A., Curcio, D. L., Maki, K. C., Davidson, M. H., & Nicholls, S. J. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2023.05.098 · Cited by 84
Self-citationTreatment Options for Statin-Associated Muscle Symptoms
Laufs, U., Scharnagl, H., Halle, M., Windler, E., Endres, M., & März, W. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0748 · Cited by 84
Millwood, I. Y., Bennett, D. A., Holmes, M. V., Boxall, R., Guo, Y., Bian, Z., Yang, L., Sansome, S., Chen, Y., Du, H., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4177 · Cited by 81
“If the composition of VLDL particles is altered, aswithgenetic orpharmacologicCETP inhibition, then this alteration may affect the comparability of LDL cholesterol levels measured directly or estimated using the Friedewald formula.(34) Although inverse associations between HDL cholesterol concentration and occlusive C…”
MethodNelson, A. J., Sniderman, A. D., Ditmarsch, M., Dicklin, M. R., Nicholls, S. J., Davidson, M. H., & Kastelein, J. J. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169417 · Cited by 67
“ultracentrifugation, which is the gold standard measurement, was also conducted in 2000 subjects in REVEAL [44,45].”
BackgroundMethodSelf-citationLandray, M. J., & REVEAL Collaborative Group (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.02.021 · Cited by 68
“07 Medication ACE inhibitor or ARB 11,879 (75%) 4400 (72%) 4050 (47%) 20,329 (67%) Antiplatelet therapy 14,261 (91%) 5654 (93%) 7992 (93%) 27,907 (92%) Diuretic 3965 (25%) 1831 (30%) 728 (8%) 6524 (21%) Calcium-channel blocker 4045 (26%) 1461 (24%) 2679 (31%) 8185 (27%) β-Blocker 10,897 (69%) 4665 (77%) 5112 (59%) 20,…”
Cupido, A. J., Reeskamp, L. F., Hingorani, A. D., Finan, C., Asselbergs, F. W., Hovingh, G. K., & Schmidt, A. F. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2333 · Cited by 68
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55-REVEAL Collaborative Group, Sammons, E. L., Hopewell, J. C., Chen, F., Stevens, W., Wallendszus, K., Valdés‐Márquez, E., Dayanandan, R., Knott, C., Murphy, K., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab863 · Cited by 67
“During the in-trial period, it emerged that LDL cholesterol levels measured by a direct assay may be underestimated in those treated with anacetrapib compared with the gold standard betaquantification method.(1,6) Therefore, further descriptions in this manuscript are framed in the context of non-HDL cholesterol rathe…”
Self-citationDong, B., Singh, A. B., Fung, C., Kan, K. K. W., & Liu, J. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.05.931 · Cited by 62
“With regard to its effect on LDL-C reduction, a recent new study to compare different methods to determine LDL-C levels in placebo and ANA treated patients suggested that the true LDL-C reductions with this CETP inhibitor may have been less than reported, while its inductions on HDL-C were unaffected by different meas…”
ResultAccuracy of low-density lipoprotein cholesterol estimation at very low levels
Quispe, R., Hendrani, A. D., Elshazly, M. B., Michos, E. D., McEvoy, J. W., Blaha, M. J., Banach, M., Kulkarni, K. R., Toth, P. P., Coresh, J., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0852-2 · Cited by 53
Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values
Rosenson, R. S., & Underberg, J. A. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6477-6 · Cited by 47
“These included the Stop Atherosclerosis in Native Diabetics Study (SANDS) [43] and a study evaluating the CETP inhibitor dalcetrapib [44].”
MethodGotto, A. M., Kher, U., Chatterjee, M. S., Liu, Y., Li, X. S., Vaidya, S., Cannon, C. P., Brinton, E. A., Moon, J. E., Shah, S., et al. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414529621 · Cited by 45
“A subsequent analysis showed that compared to the reference b-quantification method, the Friedewald equation underestimates LDL-C levels after treatment with anacetrapib, so that the actual degree of LDL-C reduction may have been less than originally reported.(3) A 2-year extension to the DEFINE study was conducted to…”
ResultSelf-citationPharmacotherapies for lipid modification: beyond the statins
Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 46
Self-citationReliability of Calculated Low-Density Lipoprotein Cholesterol
Meeusen, J. W., Snozek, C. L. H., Baumann, N. A., Jaffe, A. S., & Saenger, A. K. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.05.013 · Cited by 44
Laufs, U., Scharnagl, H., & März, W. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000236 · Cited by 43
Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism
Schaefer, E. J. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283612454 · Cited by 34
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
“and (d) cholesterol ester transfer protein (CETP) [11,12].”
BackgroundInfluentialLim, S.-M., Kim, E., Shin, J.-H., Seok, P. R., Jung, S., Yoo, S., & Kim, Y. (2018) · Molecules · doi:10.3390/molecules23030705 · Cited by 32
“Concentration of low-density lipoprotein cholesterol (LDL-C) and VLDL-C [73] as well as AI values [39,74], were calculated according to the following formulas.”
MethodInfluentialTeramoto, T., Shirakawa, M., Kikuchi, M., Nakagomi, M., Tamura, S., Surks, H. K., Sisk, C. M., & Numaguchi, H. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.05.012 · Cited by 31
“This variability is due to an overestimation of VLDL-C by the TG/5 component of the Friedewald equation and an underestimation of LDL-C after treatment with ANA [10,27].”
BackgroundMethodBarter, P. J., Nicholls, S. J., Kastelein, J. J. P., & Rye, K.-A. (2015) · Circulation · doi:10.1161/circulationaha.114.014025 · Cited by 33
“Anacetrapib decreased the level of lDl-C from 81 to 45 mg/dl, an apparent 40% reduction compared with that seen with the placebo, although the use of the Friedwald equation to assay lDl-C in this study resulted in an overestimation of the true reduction, which was probably closer to 30%.(61) The concentration of non–H…”
ResultSelf-citationBrinton, E. A., Kher, U. A., Shah, S., Cannon, C. P., Davidson, M. H., Gotto, A. M., Ashraf, T. B., Sisk, C. M., Dansky, H. M., Mitchel, Y., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.10.005 · Cited by 28
“A subsequent assay comparison study demonstrated that the Friedewald formula(11) underestimates LDL-C levels after treatment with anacetrapib relative to the reference beta-quantification method.(12) Thus, the actual reduction in LDL-C with anacetrapib may be closer to 25% to 35%, although the exact magnitude is unkno…”
MethodSelf-citationRehman, W. U., Yarkoni, M., Ilyas, M. A., Athar, F., Javaid, M., Ehsan, M. T., Khalid, M. T., Pasha, A. K., Selma, A. B., Yarkoni, A., et al. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050152 · Cited by 31
“Nonetheless, the Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trial demonstrated a significant reduction in MACEs that was directly correlated with reductions in non-HDL-C molecules [12,19,26–28].”
LDL cholesterol: How low to go?
Packard, C. J. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.12.011 · Cited by 21
Cholesteryl Ester Transfer Protein Inhibitors: Trials and Tribulations
McLain, J. H., Alsterda, A. J., & Arora, R. R. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416662349 · Cited by 23
“Anacetrapib also showed a striking ability to remain in the body, with residual plasma levels at *40% of on-treatment concentration detected at 12 weeks posttreatment, and patients returning for 4-year follow-ups still had detectable levels.(47,48) The REALIZE was a phase 3, double-blind, placebocontrolled study that…”
BackgroundMartin, S. S., Ditmarsch, M., Simmons, M., Alp, N., Turner, T. A., Davidson, M. H., & Kastelein, J. J. P. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac056 · Cited by 23
Self-citationZhou, J., Bai, J., Guo, Y., Fu, L., & Xing, J. (2021) · Gynecologic and Obstetric Investigation · doi:10.1159/000510032 · Cited by 19
Ballantyne, C. M., Shah, S., Sapre, A., Ashraf, T. B., Tobias, S. C., Şahı̇n, T., Ye, P., Dong, Y., Sheu, W. H., Kang, D., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.03.255 · Cited by 16
Self-citationTeramoto, T., Daida, H., Ikewaki, K., Arai, H., Maeda, Y., Nakagomi, M., Shirakawa, M., Watanabe, Y., Kakikawa, T., Numaguchi, H., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.009 · Cited by 15
Ballantyne, C. M., Shah, S., Kher, U. A., Hunter, J. A., Gill, G. G., Cressman, M. D., Ashraf, T. B., Johnson‐Levonas, A. O., & Mitchel, Y. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.10.032 · Cited by 15
Self-citationArai, H., Teramoto, T., Daida, H., Ikewaki, K., Maeda, Y., Nakagomi, M., Shirakawa, M., Kakikawa, T., Numaguchi, H., Johnson‐Levonas, A. O., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.017 · Cited by 11
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 16
Tsai, C.-H., Wu, H., & Weng, S.-J. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-113 · Cited by 8
“This method also tends to underestimate LDL-C concentrations [6,14-18] when the triglyceride concentration is normal [19,20] or less than 400 mg/dL [4,6,21,22].”
MethodLower LDL is better – can this be achieved with CETP inhibition therapy?
Rashid, S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1715797 · Cited by 7
Timón-Zapata, J., Mendieta, E. J. L., Sáenz-Mateos, L. F., Ruiz-Trujillo, L., Fernández, A. A., Palomino-Muñoz, T. J., Loeches-Jiménez, M. P., & Gómez-Serranillos, M. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.12.043 · Cited by 4
Habashy, W. S., Morsi, A., Elghalid, O. A., El-Hady, A. M. A., & Elnaggar, A. S. (2026) · Tropical Animal Health and Production · doi:10.1007/s11250-026-04862-9 · Cited by 2
“High-density lipoprotein (HDL) levels were determined using the method of Warnick et al. (1983 ), while low-density lipoprotein (LDL) levels were calculated using the formula: LDL = Total Cholesterol – ( HDL + Triglycerides/5 ) , as outlined by Davidson et al. (2013).”
Cholesteryl Ester Transfer Protein Inhibitors
Inazu, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-407867-3.00008-1 · Cited by 3
Ali, A., & Duffy, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12463-1 · Cited by 2
A Contemporary Evaluation of Calculated and Directly Measured LDL
Lau, C. S., Loh, W. J., Phua, S. K., & Aw, T. C. (2021) · Japan Journal of Clinical & Medical Research · doi:10.47363/jjcmr/2021(1)109 · Cited by 2
Burger, P. M., Dorresteijn, J. A. N., Koudstaal, S., Ridker, P. M., Mosterd, A., & Visseren, F. L. J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119225 · Cited by 2
Advances in Hypercholesterolemia
Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 3
New Treatment Approaches for Dyslipidemia and its Management
Vorsanger, M., & Underberg, J. A. (2013) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-013-0333-x
“Anacetrapib and evacetrapib, are newer agents and are both more potent inhibitors of CETP as well as reducers of LDL [33, 34].”
BackgroundAnacetrapib: potential for the prevention and treatment of coronary heart disease
Cannon, C. P., Steen, D. L., & Khera, A. V. (2013) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s27769
“The Phase II study of evacetrapib measured LDL-C by using an enzymatic method; enzymatic assays are expected to produce LDL-C values closer to those of the β-quantification method.(97) In terms of safety endpoints, anacetrapib demonstrated no increase in side effects (including myalgia), drug-related adverse effects,…”
Self-citationNew targets and developments in lipoproteins control
Norata, G. D. (2013) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s34904
“20%) reduced LDL-C by 40% with no changes in blood pressure or serum aldosterone levels.(21,22) In a Phase II study, evacetrapib (30 mg, 100 mg, or 500 mg daily) increased HDL-C levels (+53.”
BackgroundMasana, L. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2017.10.002
Statin Intolerance: Diagnosis and Management
Khanna, R., & Himanshu, D. (2017) · Indian Journal of Cardiovascular Disease in Women · doi:10.1055/s-0037-1607193
Results of the REVEAL study. Why should we not welcome a new lipid-lowering agent?
Masana, L. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.11.003
Jaber, A. R., Zayed, J. A., Alabed, Z., Zapen, J., & Ayesh, H. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-026-00590-5 · Cited by 2
“Cholesteryl ester transfer protein (CETP) inhibitors are among these newer therapeutic options [5].”
Metadata
- Authors
- Davidson, M., Liu, S. X., Barter, P., Brinton, E. A., Cannon, C. P., Gotto, A. M., Leary, E. T., Shah, S., Stepanavage, M., Mitchel, Y., & Dansky, H. M.
- Affiliations
- University of Chicago (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- The Heart Research Institute (AU)
- Foundation for Biomedical Research (US)
- Brigham and Women's Hospital (US)
- Weill Cornell Medicine (US)
- Pacific Biomarkers (United States) (US)
- Corresponding author
- Davidson, Michael
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 54
- Issue
- 2
- Pages
- 467-472
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC3588873
- OpenAlex
- W2108169863
- Cited by
- 56
- References
- 19
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 12 · 2016: 5 · 2015: 5 · 2014: 6 · 2013: 10
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 2819 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Keywords
- LDL cholesterol estimation, anacetrapib, cholesteryl ester transfer protein inhibitors, Friedewald formula, VLDL cholesterol, triglyceride elevation, assay bias
- MeSH terms
- Aged, Blood Chemical Analysis, Clinical Trials as Topic, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Chemical Precipitation, Reference Standards, Time Factors, Ultracentrifugation, Dextran Sulfate, Oxazolidinones, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.